KACH collaboration garners FDA approval of TBI diagnosis device; device recognized by TIME

WEST POINT, N.Y. — The Keller Army Community Hospital Orthopaedic and Sports Medicine Research team, led by Kenneth L. Cameron, PhD, MPH, ATC, FNATA, D… WEST POINT, N.Y. — The Keller Army Community Hospital Orthopaedic and Sports Medicine Research team, led by Kenneth L. Cameron, PhD, MPH, ATC, FNATA, Director, John A. Feagin Sports Medicine Fellowship, Keller Army Community Hospital, West Point, N.Y., and the team at Oculogica, developed an invention that was named to Time’s list of the Best Inventions of 2026 (https://time.com/collection/best-inventions/2026/). In May 2021, the U.S. Army Medical Research and Development Command (USAMRDC) awarded Oculogica, Inc., a $2 million contract to develop a faster, field-ready version of its eye-tracking concussion technology.

Five years later, that investment has produced something that often takes far more money and time: an FDA-cleared medical device, on the market and in use. The device is SNAP, a 90-second concussion assessment. It received FDA clearance on June 5, 2026, as an aid in the diagnosis of concussion in patients ages 15 to 25. In clinical testing, SNAP identified concussion with 89.6% sensitivity and 93.6% specificity. Concussion is one of the most common injuries in military training and operations, and it is often hard to detect. Symptoms can be subtle, and service members may underreport them. SNAP combines eye tracking, which measures how the